Identity recordProduct-specific FDA and EU medicine records
What SCENESSE resolves to
SCENESSE is a product-specific afamelanotide 16 mg implant authorized in the United States and European Union for narrowly defined erythropoietic protoporphyria uses. Those authorizations do not transfer to seller-labelled Melanotan I research vials, compounded products, other presentations, indications, online sellers, or supply routes, and they do not establish local availability in every country.
- Evidence lane
- FDA-approved medicine
- Current record
- NDA 210797 · FDA-approved prescription drug
- Checked
- July 17, 2026
afamelanotideScenesseCUV1647NDA 210797alpha-MSH analog
Destination recordConsulta en registros de ANMAT
What Argentina still has to prove
Guía argentina para investigar nombres de péptidos sin confundir una coincidencia de ingrediente, una oferta importada o una etiqueta de investigación con un medicamento registrado y una vía de suministro verificada.
- Comparison mode
- ARS / medicamento, titular y establecimiento
- Price coverage
- Sin tabla comercial calificada para Argentina
- Guide updated
- 18 de julio de 2026